Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRY-371797 in Active Ankylosing Spondylitis
NCT00811499Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of emprumapimod in ankylosing spondylitis (AS), sponsored by Pfizer. Started Dec 2008; status: terminated.
02
Drugs
emprumapimod
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00811499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811499.